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Abstract 
In this thesis, I developed ribosome-mediated thioester bond formation and its 
applications. Enen though it has been shown that engineering of the translation apparatus 
allows for incorporating or even polymerizing analogs of α-amino acids, such as 
N-alkyl-amino acids and α-hydroxy acids (lactic acids), there had been no clear report of 
successful thioester bond formation in ribosome so far.  
 In chapter 2, I demonstrated the ribosome-mediated thioester bond formation 
using our Flexible In-vitro Translation (FIT) system, where the genetic code 
reassignment is facilitated by flexizymes and a reconstituted E. coli in-vitro translation 
system. This is the first clear report for thioester bond formation by ribosome. This 
technique was applied to native chemical ligation (NCL) of peptide and even protein that 
is not usually accessible by chemical synthesis. Here the semi-synthesis of a yellow 
fluorescent protein, VENUS was performed by NCL of the truncated VENUS-thioester 
expressed by in vitro translation to the synthetic peptide, demonstrating the utility of 
ribosome-mediated thioester bond formation. 
 In chapter 3, I applied the ribosome-mediated thioester bond formation for 
backbone macrocyclization of peptides. Although backbone-cyclized peptides are 
increasingly expected as a promising drug scaffold due to their significant therapeutic 
potential, in vitro display technologies allowing for the facile construction of polypeptide 
libraries consisting of hundreds of millions to over trillions mutants and the rapid 
screening of strong and selective binders to target proteins have not been compatible with 
backbone-cyclized peptides. This is because backbone macrocyclization would involve 
the disruption of indispensable linkage for in vitro displays between the genotype and the 
phenotype peptide. To circumvent this issue, I developed the synthesis of 
backbone-cyclized peptides compatible with in vitro display via a complex rearrangement 
strategy using ribosome-mediated thioester bond formation. 
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Flexible Catalytic Activity of Ribosome to Incorporate Non-Canonical Substrates 
In all living organisms, ribosomes synthesize proteins by polymerizing 20 
different proteinogenic amino acids using mRNA as a template in the translation system. 
The specificity of utilization of these 20 proteinogenic amino acids is determined by 
aminoacyl-tRNA synthetases (ARSs) 1 2 3. ARSs recognize the correct pairs of amino 
acid and tRNA to afford aminoacyl tRNA, enabling the decoding of mRNA according to 
the genetic code and their accommodation into ribosome. Despite the strict control of 
fidelity between codons and encoding proteinogenic amino acids in translation, it is 
known that the ribosome does not strictly recognize the substrate bound on the tRNA 4 5 6 
7 8 9. Therefore, ribosomes can incorporate or even polymerize analogs of α-amino acids 
by preparing appropriate substrate-tRNA. For example, it has been reported more than 40 
years ago that ribosomes can incorporate α-hydroxy acid into polypeptide and form an 
ester bond by supplying tRNA charged with α-hydroxy acid, called hydroxyacyl tRNA, 
to the translation system 10. In addition, the ribosomal incorporation of N-alkyl amino 
acids 11, D-amino acids 12, β-amino acids13, hydrazino acids 14, etc. have been reported so 
far.  
Recently our group has successfully demonstrated such events using our 
Flexible In vitro Translation (FIT) system 15 16. The FIT system is composed of two 
technologies, flexizymes and a reconstituted E. coli in vitro translation system 17. 
Flexizymes are artificially evolved tRNA acylation ribozymes that facilitate the 
aminoacylation of tRNA using appropriately activated amino acid substrates by 
cyanomethyl ester, 3,5-dinitrobenzyl ester, etc. The flexizyme system is capable of 
charging not only a wide variety of amino acids but also various other substrates such as 
hydroxy acids, peptides, and so on. Acyl tRNAs prepared in this way are supplied to a 
custom-made reconstituted E. coli in vitro translation system, wherein some components 
are excluded in order to reassign the codons from proteinogenic to nonproteinogenic 
amino acids or other acid substrates. Thus the governance of the genetic code is 
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arbitrarily reprogrammed and this strategy is referred to as genetic code reprogramming. 
On the other hand, even though α-thio acid is similar to α-hydroxy acid, there 
had been no clear report of successful formation of thioester bond by ribosome. Although 
Schultz, P. G. et al. described ribosomal incorporation of the thiol analog of alanine in the 
early study of ribosomal incorporation of various substrates18, they did not show any data 
indicating the ribosomal α-thio acid incorporation. In addition, no follow-up studies or 
applications on the ribosomal α-thio acid incorporation have been reported. Therefore it 
remains unclear whether or not ribosomal thioester bond formation is possible and 
compatible with applications. 
 
Thioester Bond in Protein Chemistry and Chemical Biology 
 Thioester bond is an analogue of ester bond with the functional group 
R-COO-R’ replaced by R-COS-R’. Thioester bond is more hydrolytically labile than the 
ester bond, but more importantly it is readily trans-thioesterified with other thiol group 
and the latter characteristic turns out to be useful for ligating two peptide fragments, 
so-called native chemical ligation (NCL) 19. NCL is the most convenient and commonly 
used technique for selective ligation of unprotected polypeptide fragments under aqueous 
neutral conditions where the “native” peptide bond is formed via an intermediate of 
trans-thioesterified species (Figure 1). NCL was initially developed to solve the decades 
of problem on how to chemically synthesize proteins from smaller, synthetically 
accessible peptide building blocks 20 21 and peptide-thioesters for use in NCL had been 
prepared solely by chemical synthesis. Thus NCL has extended the limitation of the total 
synthesis of proteins but chemical synthesis of larger proteins beyond 20 kDa is still 
challenging 22 23. 
 To solve this problem, a semisyntheis version of NCL has been developed, 
called expressed protein ligation (EPL), where recombinant polypeptide-thioesters are 
used for ligation 24. In EPL, recombinant polypeptide-thioesters are prepared by the 
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intein-based approach utilizing a process termed protein splicing. This process is 
mediated by the autosplicing domain called intein25 via the formation of thioester 
intermediates (Figure 2). Here the intermediates can be intercepted by using appropriate 
intein mutants, and further cleaved to afford the desired thioester forms through thioester 
exchanges 26 27 (Figure 3). Thus EPL can bridge the gap between synthetic peptides and 
recombinant proteins and significantly increases the size and complexity of chemically 
synthesized proteins. This capability has been used for the production of various modified 
proteins bearing fluorophores 28 29, isotopic labeling 30 31 32, cross-linkers 33, 
posttranslational modifications 34 35, and so on.  
 Despite the success of the intein-based EPL in many protein systems, the 
generation of modified proteins via ligation can be still challenging because all proteins 
have their own sequence, structure, properties and behaviors, and thus an optimal ligation 
strategies are required on a case-by-case basis 36 37 38. Therefore the development of new 
polypeptide-thioester preparation method that does not use the intein-based approach may 
expand protein targets and applications accessible by ligation.  
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Backbone-Cyclized Peptides 
 Macrocyclic peptides are increasingly expected as a promising drug scaffold 
due to their significant therapeutic potential such as strong and selective binding affinity 
to target proteins 39, proteolytic stability 40, and possible passive membrane permeability 
conferred by intramolecular hydrogen bonds 41. The macrocyclic structure can be formed 
by linking one end of the peptide and the other with an amide bond, or other chemically 
stable bonds such as lactone, ether, thioether, disulfide, and so on. Among them, 
backbone cyclization (or head-to-tail cyclization) is amide bond formation between 
amino and carboxyl termini. Backbone-cyclized peptide is of particular interest because a 
number of biologically active macrocyclic peptides are formed this way 42. Moreover, 
several backbone-cyclized peptides found in nature are already used in clinic such as 
gramicidin 43 and tyrocidine 44 with bactericidal activity, and cyclosporin A 45 with 
immunosuppressive activity (Figure 4). In addition, cyclotides are a new emerging 
family of large plant-derived backbone-cyclized peptides with a knotted arrangement of 
three disulfide bonds 46 47. Due to their stability, biological activities like anti-HIV 48, 
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Figure 3 | Recombinant protein-thioester preparation for expressed protein ligation (EPL) 
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uterotonic 49 and insecticidal 50, and cell membrane permeability 51 52, cyclotides are 
expected as a scaffold for novel peptide drugs.  
 
To date, due to their potential as lead compounds for drugs, many efforts have 
been made to develop biologically active backbone-cyclized peptides with both synthetic 
and genetic approaches. Backbone-cyclized peptides can be synthetically prepared by 
solid phase peptide synthesis of linear peptides followed by macrocyclization using 
condensation reagents 53, enzymatic reactions 54, traceless Staudinger ligation 55, 
intramolecular NCL 56,57, and so on. Then synthetic backbone-cyclized library can be 
prepared in combination with split-and-pool synthesis 58. However, this approach has a 
limitation and difficulty in terms of library size (up to ~107) 59 and the identification of hit 
compounds because conventional Edman degradation cannot be used for cyclic peptides 
once the free N-terminus disappears after the backbone macrocyclization. Although 
tandem mass spectrometry can be used to analyze peptide sequences, the analysis of 
cyclic peptide sequence is more difficult than that of linear peptide sequence60-63.  
On the other hand, the genetic approach can circumvent these problems. This 
approach consists of two technologies. The expression of backbone-cyclized peptides 
relies on the split-intein circuit ligation of peptides and proteins (SICLOPPS) system64. In 
the SICLOPPS, the C- and N-terminal intein fragments (IC and IN, respectively) come 
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together to form an active intein that splices to give a backbone-cyclized peptide (Figure 
5). The other technology is the reverse two-hybrid system (RTHS) 65,66. The RTHS can 
couple host cell growth to the disruption of protein-protein interaction and thereby 
permits the activity-based selection of protein-protein interaction inhibitors. Thus the 
combination of SICLOPPS with RTHS allowed for the diverse library construction and in 
vivo selection of bioactive backbone-cyclized peptides67,68. The diversity is typically 
around 108, larger than that of the synthetic libraries. In addition, straightforward 
identification of hit compounds can be performed by sequencing of host cell gene.  
 Although the genetic selection with SICLOPPS has been used for the 
discovery of inhibitors against a wide variety of targets, it has several limitations. First, 
the selection condition is not versatile, and restricted as set in the context of the 
disruption of protein-protein interaction. Second, the SICLOPPS is limited to using the 
Precursor
linear peptideIC  IN 
Active intein formation 
Split intein-mediated cyclization
Backbone-cyclized peptide
Figure 5 | Expression of backbone-cyclized peptide by SICLOPPS. An expressed 
fusion peptide folds to form an active intein. The following splicing results in backbone 
macrocyclization of the target peptide. 
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20 proteinogenic acids as the building blocks, although this constraint has been partially 
removed by SICLOPPS with an orthogonal aminoacyl-tRNA synthetase/tRNACUA pair to 
add 21st amino acid69. Third, the library size is much smaller than that of the in vitro 
display technologies (~ 1014 at maximum) as described below. For a randomized peptide 
library, the diversity is of great importance, providing the opportunity for exploration of 
the sequence space to a greater depth for the search of bioactive compounds. 
 
In Vitro Display Technologies 
 In vitro display technologies such as phage display70, ribosome display71, 
mRNA display72,73, etc. allow for the facile construction of polypeptide libraries 
consisting of hundreds of millions to over trillions mutants and the rapid screening of 
strong and selective binders to target proteins. These significant features of in vitro 
display technologies are largely achieved by linking the phenotype polypeptide to the 
corresponding genotype nucleic acid. In in vitro display, “hit” molecules are typically 
selected in vitro on an affinity basis from a library consisting of genotype-phenotype 
fusions, and the recovered genotypes are amplified. Thus the iterative rounds of these 
library construction, selection and enrichment allow molecular evolution in vitro, 
followed by easy identification of the selected phenotypes by sequencing of the encoded 
genotypes (Figure 6). 
 In vitro display technologies can be separated into cellular approaches using 
cell to express and clone the polypeptide libraries and acellular approaches in which the 
libraries are expressed truly in vitro and display is achieved without the need for 
transformation. For example, phage display is a representative technique of the cellular 
approaches, where the phenotype peptides or proteins are expressed and displayed on 
bacteriophage particles that have their corresponding DNAs inside. The cellular 
approaches also include yeast cell display74 and bacterial display75. Despite the versatility 
of phage display, however, it has the limitations, particularly in terms of speed and library 
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diversity. This is mainly because transformation, the process which is indispensable for 
the cellular approaches, is inefficient and sets a practical threshold of ~109 clones76, 
leading to a poor probability of affinity hits. This is the reason why the development of 
the acellular approaches has been prompted. The first cell-free in vitro display is 
ribosome display, and in ribosome display the genotype mRNA templates are connected 
with the nascent peptides in a complex with ribosome. mRNA display is a related 
technique and differentiates itself from ribosome display by the formation of covalent 
link between the mRNA templates and the expressed peptides via puromycin linker. In 
addition, DNA-based displays have also been developed where phenotype peptides and 
genotype DNA (not mRNA) are linked via DNA binding proteins77,78. Consequently, 
diverse libraries with as many as 1012 to 1014 unique sequences can be readily generated 
with these cell-free displays, which are several orders of magnitude higher than phage 
display79. 
 On the other hand, the classic in vitro display technologies have a limitation 
that the displayed libraries are principally restricted to the 20 proteinogenic amino acid 
building blocks since the library generation depends on ribosomal synthesis, limiting the 
functions and structural motifs that can be explored. To overcome this issue, our group 
has recently developed a novel nonstandard peptide screening technology, referred to as 
RaPID (Rapid non-standard Peptide Integrated Discovery) display, by integrating mRNA 
display with the FIT system, a convenient genetic code reprogramming technique as 
mentioned above. We have already reported various nonstandard peptide libraries such as 
thioether macrocyclic peptide libraries80,81, including N-methylated peptide libraries82 and 
those with mechanism-based chemical warheads to the target proteins83 expressed by the 
RaPID display. Thus the RaPID display has greatly expanded not only the sequence 
space of peptide libraries but also the diversity of structures and chemical entities in the 
peptides. However, even the RaPID display, as well as other in vitro displays, still has a 
limitation in terms of peptide structures to be expressed. For example, backbone-cyclized 
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peptides have not been compatible with the RaPID display. In mRNA display including 
the RaPID display, genotype mRNA is covalently linked to the C-terminus of 
downstream peptide via puromycin linker. This linkage allows for iterative rounds of 
selection and amplification shown in Figure 6 and thereby is indispensable for mRNA 
display. Backbone-cyclized peptides can be ribosomally synthesized by expressing 
peptides possessing N-terminal cysteine and C-terminal thioester followed by 
intramolecular NCL. In this backbone macrocyclization, however, the peptide 
downstream of thioester connected with mRNA always works as a leaving group and 
genotype-phenotype linkage is disrupted. Thus backbone-cyclized peptides have not been 
compatible with mRNA display (Figure 7).  
  
 
 
 
 18 
 
 
Figure 6 | Scheme of in vitro display using mRNA display as an example. In mRNA display, 
phenotype-genotype fusion is prepared in which phenotype and genotype are covalently connected 
via puromycin. Then target-binding peptide-mRNA fusions are selected from the library on an affinity 
basis. Selected mRNA sequences are amplified by reverse transcription, PCR, and transcription to 
afford an mRNA library. Thus obtained mRNAs are used for construction of next-generation peptide 
library or for identification of hit peptides by sequencing.  
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Figure 7 | Backbone macrocyclization disrupting the linkage between genotype and 
phenotype. In this figure, backbone macrocyclization using intramolecular NCL is 
illustrated, but other backbone macrocyclization methods would also disrupt the linkage 
and not be compatible with mRNA display nor other in vitro display techniques. 
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Ribosome-Mediated Thioester Bond Formation (a Brief Introduction of Chapter 2) 
 As described above, ribosome-mediated thioester bond formation has not been 
shown nor used even though thioesters in polypeptides are turned out to be of great use in 
protein chemistry and chemical biology. Thus, the alternative recombinant protein 
thioester preparation methods have been developed and applied. However, if thioester 
bond formation by ribosome were turned out to be possible and compatible with 
applications, it would be an alternative technique for preparation of site-selectively 
thioester-incorporated proteins and peptides. 
Therefore, in chapter 2, we investigated ribosome-mediated thioester bond 
formation by using the FIT system. Especially, the flexizymes were used for the easy 
preparation of thioacyl tRNAs, which were tRNAs charged with thio acid and 
indispensable for ribosomal incorporation of α-thio acids. Furthermore, a 
proof-of-concept application of ribosomal thioester bond formation toward NCL was 
studied. Here the NCL of VENUS, a yellow fluorescent protein, was demonstrated. 
 
Backbone-Cyclized Peptides Compatible with In Vitro Display (a Brief Introduction 
of Chapter 3) 
Since the backbone-cyclized peptides are attractive lead compounds for drugs 
as mentioned above, a high-throughput screening method from a highly diverse 
backbone-cyclized peptide library is expected to be developed. For that purpose, mRNA 
display including the RaPID display has notable advantages. First, diverse libraries with 
as many as 1012 to 1014 unique sequences can be readily generated and screened, which is 
several orders of magnitude higher than the genetic selection with SICLOPPS. Second, 
the covalent linkage of the peptide to its mRNA makes it possible to set arbitrary 
conditions in a selection in vitro. However, mRNA display, as well as other in vitro 
displays, has not been compatible with backbone-cyclized peptides since genotype leaves 
off from phenotype backbone-cyclized peptide in macrocyclization as mentioned above. 
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To overcome this issue, I speculated that an additional covalent bond linkage formation 
between genotype and phenotype would enable backbone-cyclized peptides to be used for 
in vitro display.  
 In chapter 3, the backbone macrocyclization compatible with mRNA display 
via a complex rearrangement strategy was investigated to realize this idea. The strategy 
was made possible with ribosome-mediated thioester bond formation, demonstrating the 
utility of this straightforward polypeptide thioester preparation method. 
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To date, ribosome-mediated thioester bond formation has not been 
demonstrated nor used for applications despite the fact that not only peptide bond (amide 
bond) but also other analogues of peptide bond such as N-alkyl amide bond and ester 
bond can be formed by ribosome. Although the alternative recombinant protein thioester 
preparation methods such as intein-based approaches have been developed due to the 
utility of thioester bond, I envisioned that direct ribosome-mediated thioester bond 
formation would provide a at least supplementary or possibly better technique depending 
on the kinds of applications. Thus ribosome-mediated thioester bond formation was 
clearly demonstrated for the first time to our best knowledge in chapter 2. In addition, its 
utility was also demonstrated with NCL of a yellow fluorescent protein, VENUS. 
Although only such a proof-of-concept experiment was performed in this thesis for 
application to NCL, this original thioester bond formation method has several features 
and advantages that differentiate itself from other alternative methods. For example, in 
intein-based approaches, the size of intein (>150 aa) could be problematic for NCL of 
protein because it could disrupt the forming secondary or tertiary structure of 
protein-intein fusion depending on the insertion site. This drawback could be solved by 
my method because incorporation of one residue of α-thio acid, HSFp-Cl would be less 
likely to influence the forming structure. In addition, thioester bond is prepared by 
conversion from thioester equivalent via N to S acyl shift from cysteine thiol in a lot of 
alternative methods, whereas thioester bond is directly formed by ribosome in my method. 
Thus possibly slow and inefficient thiolysis step can be omitted in my method. Besides, 
downstream peptide of thioester can be used for application, and no cysteine is required 
to form thioester bond in my method. These features would possibly make novel 
applications that are not accessible by alternative methods.  
In fact, the features are largely utilized for backbone macrocyclization of 
peptides performed in chapter 3. In this chapter, backbone macrocyclization of peptides 
compatible with mRNA display was achieved via a complex rearrangement strategy 
where ribosome-mediated thioester bond formation, spontaneous thioether bond 
formation after translation, N-terminal MeCys liberation, and intramolecular NCL occur. 
Backbone-cyclized peptides have not been compatible with in vitro displays because 
backbone macrocyclization would disrupt the indispensable linkage between the 
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genotype and the phenotype peptide. I speculated that this was circumvented by an 
additional side chain-to-side chain covalent bond linkage formation between genotype 
and phenotype before the macrocyclization. I used thioether bond formation reaction 
between chloroacetyl group and thiol for the linkage because this reaction has desirable 
characteristics for mRNA display. First, genetic incorporation of only one non-canonical 
residue, Cab, is needed for the bond formation and thereby the limited resource of 
building blocks to be used in ribosomal synthesis can be saved. Second, since this 
reaction occurs fast and spontaneously, reducing the possibility of thioester hydrolysis 
and any extra steps such as addition of reagents and purification. Importantly, this 
reaction could be used in the strategy by ribosome-mediated thioester bond formation. In 
the alternative methods, not downstream cysteine but cysteine in thioester equivalent 
would react with Cab, resulting in no thioester bond formation nor backbone 
macrocyclization. Intein-based approaches are not favorable especially for the RaPID 
display because expression of intein requires 20 proteinogenic amino acids, making 
ribosomal incorporation of other non-canonical substrates and expression of libraries with 
diverse structures and chemical entities impossible. In the strategy using 
ribosome-mediated thioester bond formation, backbone cyclized peptides maintaining 
downstream peptide were successfully obtained even though thiol-thioester exchange was 
observed with downstream cysteine. mRNA display can readily generate and screen 
diverse libraries with as many as 1012 to 1014 unique sequences, which is several orders of 
magnitude higher than the genetic selection using SICLOPPS with up to 109 sequences.	
For a randomized peptide library, the diversity is of great importance, providing the 
opportunity for exploration of the sequence space to a greater depth for the search of 
bioactive compounds. Thus this result would be an important milestone toward the goal 
of the screening of drug candidates with a backbone-cyclized peptide scaffold. 
The studies carried out in this thesis have validated the utility of 
ribosome-mediated thioester bond formation for not only classic native chemical ligation 
but also a backbone-peptide cyclic scaffold of peptides via a complex rearrangement 
strategy compatible with in vitro display. Particularly, not other alternative 
peptide-thioester preparation medthods but only ribosome-mediated thioester bond 
formation could be used for the strategy for the synthesis of the backbone-cyclized 
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peptides. Thus, this novel and original thioester bond formation method would extend the 
range of accessible applications and contribute to the development of protein chemistry 
and chemical biology. 
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